por
Devillier, Raynier,
Mansat-De Mas, Véronique,
Gelsi-Boyer, Veronique,
Demur, Cecile,
Murati, Anne,
Corre, Jill,
Prebet, Thomas,
Bertoli, Sarah,
Brecqueville, Mandy,
Arnoulet, Christine,
Recher, Christian,
Vey, Norbert,
Mozziconacci, Marie-Joelle,
Delabesse, Eric,
Birnbaum, Daniel
Publicado 2015
“…ASXL1 mutations (n=26, 21%) were associated with a higher proportion of marrow dysgranulopoiesis (mutant vs. wild-type: 75% vs. 55%, p=0.030) and were mostly found in intermediate cytogenetic AML (23/26) in which they predicted inferior 2-year overall survival (
OS, mutant vs. wild-type: 14% vs. 37%, p=0.030). TP53 mutations (n=28, 22%) were mostly found in complex karyotype AML (26/28) and predicted poor outcome within unfavorable cytogenetic risk AML (mutant vs. wild-type: 9% vs. 40%, p=0.040). …”
Enlace del recurso
Enlace del recurso
Online
Artículo
Texto
